Detected ·
Oyster Therapeutics
$60MSeries A
Oyster Therapeutics (formerly Kesmalea Therapeutics) raised a $60 million Series A led by 4BIO Capital to advance its oral, brain-penetrant tau degrader and SELFTAC® platform for neurodegenerative diseases like Alzheimer's.
- Website
- —
- linkedin.com/company/98348645
- Amount
- $60 000 000 USD
- Stage
- Series A
- Event
- Funding round
- Detected
- 2026-11-10 16:04:46 UTC
- Signal ID
- 8668edef-bd7e-41a2-a6b5-872ded210ffb
As the API returns it
{
"id": "8668edef-bd7e-41a2-a6b5-872ded210ffb",
"created_at": "2026-11-10T16:04:46.400496Z",
"company_name": "Oyster Therapeutics",
"company_website_url": null,
"company_linkedin_url": "https://www.linkedin.com/company/98348645",
"event_type": "funding",
"funding_amount": 60000000,
"funding_currency": "USD",
"funding_stage": "series_a",
"message": "*Oyster Therapeutics (formerly Kesmalea Therapeutics) raised a $60 million Series A led by 4BIO Capital to advance its oral, brain-penetrant tau degrader and SELFTAC® platform for neurodegenerative diseases like Alzheimer's.*"
}